Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,543 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Treatment Regimen Clear all
Recruiting Phase 3 Interventional

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

NCT07817251
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CagriSema
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
40
States / cities
Gilbert, Arizona • Fountain Valley, California • Glendora, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 3:13 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

NCT04551131
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
Ruxolitinib, Dexamethasone, Etoposide
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Weeks to 22 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 23, 2026, 3:13 AM EDT
Terminated Phase 3 Interventional Results available

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

NCT03194646
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Standard of care
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
94
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 23, 2026, 3:13 AM EDT
Withdrawn Not applicable Interventional

Restricted Fluid Regimen in Open Abdominal Bowel Surgery

NCT00456703
View directory record Official record
Conditions
Bowel Surgery
Interventions
intraoperative fluid management, fluid restriction
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 23, 2026, 3:13 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

NCT02814669
View directory record Official record
Conditions
Castrate-Resistant Prostate Cancer
Interventions
Atezolizumab, Radium-223 Dichloride
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Duarte, California • San Francisco, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 23, 2026, 3:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

NCT00039741
View directory record Official record
Conditions
HIV Infections
Interventions
NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
30 Days to 18 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
29
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 23, 2026, 3:13 AM EDT
Completed Not applicable Interventional

Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program

NCT00792454
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Kidney Disease, Cardiovascular Disease
Interventions
exercise training
Behavioral
Lead sponsor
MaineHealth
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 23, 2026, 3:13 AM EDT
Active, not recruiting Not applicable Interventional

Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)

NCT06215469
View directory record Official record
Conditions
Breast Cancer, Early-stage Breast Cancer, Hair Loss, Alopecia, Chemotherapy-induced Alopecia
Interventions
Amma Portable Scalp Cooling System (PSCS), Questionnaires
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 23, 2026, 3:13 AM EDT
Terminated Phase 4 Interventional Results available

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)

NCT01068873
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir plus maraviroc
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 23, 2026, 3:13 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

NCT01708629
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 23, 2026, 3:13 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)

NCT00883129
View directory record Official record
Conditions
Scleroderma, Interstitial Lung Disease
Interventions
Mycophenolate mofetil, Cyclophosphamide, Placebo
Drug
Lead sponsor
Michael Roth
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 23, 2026, 3:13 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00057837
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
G-CSF, Cisplatin, Etoposide, Irinotecan, Topotecan
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
79
States / cities
Lewes, Delaware • Newark, Delaware • Jacksonville, Florida + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 23, 2026, 3:13 AM EDT
Completed Not applicable Interventional

Exercise for People with Spinal Cord Injury

NCT04007445
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Formally Directed Group (Exercise Group), Self-Directed Group (Control Group)
Behavioral · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 23, 2026, 3:13 AM EDT
Completed Not applicable Interventional Results available

Clinical Trial of Smoking Cessation Mobile Phone Program

NCT02656745
View directory record Official record
Conditions
Nicotine Addiction, Drug Addiction, Drug Dependence, Substance Use Disorder, Tobacco Dependence
Interventions
Mobile Smoking Cessation Solution
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 23, 2026, 3:13 AM EDT
Active, not recruiting Phase 3 Interventional

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

NCT00734877
View directory record Official record
Conditions
Multiple Myeloma
Interventions
M-VTD-PACE, TT3-LITE Regimen (L-TT3)
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 3:13 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

NCT04585477
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
Interventions
AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 3:13 AM EDT
Completed No phase listed Observational

Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab

NCT03200977
View directory record Official record
Conditions
Lymphoma
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Lawrenceville, New Jersey • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 23, 2026, 3:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Hematopoietic Stem Cell Transplant in Devic's Disease

NCT00787722
View directory record Official record
Conditions
Devic's Disease
Interventions
Hematopoietic Stem Cell Transplantation, Cyclophosphamide, G-CSF, rATG, Mesna, Rituximab, Methylprednisolone
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 23, 2026, 3:13 AM EDT
Completed Not applicable Interventional Results available

Cooling Pillow for Atopic Dermatitis

NCT01132651
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Current standard eczema treatment and standard pillow at night, Chillow cooling pillow
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 23, 2026, 3:13 AM EDT
Recruiting No phase listed Observational

Observational Study Protocol: LIVER-R

NCT06252753
View directory record Official record
Conditions
Hepatobiliary Cancers
Interventions
Durvalumab-based combination therapies in observational study setting, Non Durvalumab-based therapies in observational study setting, Durvalumab-based combination therapies in observational study settings
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 3:13 AM EDT
Withdrawn Phase 1 Interventional

US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

NCT04594031
View directory record Official record
Conditions
Sickle Cell Disease, Umbilical Cord Blood, Hematopoietic Cell Proliferation
Interventions
ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Biological
Lead sponsor
ExCellThera inc.
Industry
Eligibility
5 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Palo Alto, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 23, 2026, 3:13 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of the Analgesic Efficacy of Multimodal Pain Control Regimens That Aim to Limit the Use of Narcotics in Cholecystectomy and Hernia Repairs

NCT06095453
View directory record Official record
Conditions
Acute Pain
Interventions
Pain control regimens
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 23, 2026, 3:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

NCT01347645
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
FOLFIRI, E7820
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • West Palm Beach, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 23, 2026, 3:13 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer

NCT00005051
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, cisplatin, paclitaxel, topotecan hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Fresh Meadows, New York • New York, New York • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 23, 2026, 3:13 AM EDT